Evidence map›Paper›PMID 38763935›Full record

SynthesisNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2024

Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer's disease: a meta-analysis of randomized controlled trials.

Gabriel Marinheiro, Julyana Medeiros Dantas, Antonio Mutarelli, Artur Menegaz de Almeida, Gabriel de Almeida Monteiro, Djinane Spinosa Zerlotto, João Paulo Mota Telles

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Dose-Dependent efficacy and safety of Brexpiprazole in agitation associated with dementia in Alzheimer's disease: A systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Brexpiprazole for the Treatment of Agitation Associated with Dementia due to Alzheimer's Disease: Clinical Perspectives.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2026
    Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Gabriel MarinheiroSchool of Medicine, Federal University of Ceará, Sobral, Brazil. gabrielmarinheirosb@gmail.com.ORCID http://orcid.org/0009-0001-8040-6515
Julyana Medeiros DantasDepartment of Clinical Medicine, Federal University of Rio Grande Do Norte, Natal, Brazil.
Antonio MutarelliSchool of Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil.
Artur Menegaz de AlmeidaSchool of Medicine, Federal University of Mato Grosso, Sinop, Brazil.
Gabriel de Almeida MonteiroSchool of Medicine, Federal University of Ceará, Sobral, Brazil.
Djinane Spinosa ZerlottoDepartment of Medicine, State University of Campinas, Campinas, Brazil.
João Paulo Mota TellesDepartament of Neurology, University of São Paulo, São Paulo, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent randomized controlled trials (RCTs) have shown a benefit of brexpiprazole in managing agitation in patients with Alzheimer's disease (AD). However, its efficacy and safety remain unclear. We systematically searched PubMed, Embase, and Cochrane Library for RCTs comparing brexpiprazole with placebo in patients with agitation and AD. Three studies comprising 1,048 patients were included. In patients with agitation and AD, brexpiprazole significantly improved the Cohen-Mansfield Agitation Inventory total score (CMAI) at any dose (MD -3.05; 95% CI -5.12, -0.98; p < 0.01; I

Indexed as

Alzheimer DiseasePsychomotor AgitationQuinolonesThiophenesAntipsychotic AgentsHumansRandomized Controlled Trials as TopicTreatment OutcomeAntipsychotic AgentsbrexpiprazoleQuinolonesThiophenesAlzheimer’s diseaseAntipsychoticBrexpiprazoleDementiaMeta-analysis

Identifiers

PMID38763935

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.